A response to “Personalised medicine and population health: breast and ovarian cancer”-Reference-Cited by-同舟云学术

A response to “Personalised medicine and population health: breast and ovarian cancer”

Published:2019-02-27 Issue:3 Volume:138 Page:287-289
ISSN:0340-6717
Container-title:Human Genetics
language:en
Short-container-title:Hum Genet

Author:

Antoniou Antonis,Anton-Culver Hoda,Borowsky Alexander,Broeders Mireille,Brooks Jennifer,Chiarelli Anna,Chiquette Jocelyne,Cuzick Jack,Delaloge Suzette,Devilee Peter,Dorval Michael,Easton Douglas,Eisen Andrea,Eklund Martin,Eloy Laurence,Esserman Laura^ORCID,Garcia-Closas Montserrat,Goldgar David,Hall Per,Knoppers Bartha Maria,Kraft Peter,La Croix Andrea,Madalensky Lisa,Mavaddat Nasim,Mittman Nicole,Nabi Hermann,Olopade Olufunmilayo,Pashayan Nora,Schmidt Marjanka,Shieh Yiwey,Simard Jacques,Stover-Fiscallini Allison,Tice Jeffrey A.,van’t Veer Laura,Wenger Neil,Wolfson Michael,Yau Christina,Ziv Elad

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Genetics

Link

http://link.springer.com/article/10.1007/s00439-019-01984-z/fulltext.html

Reference11 articles.

1. Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 289:3243. https://doi.org/10.1001/jama.289.24.3243

2. Cuzick J, Warwick J, Pinney E et al (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. JNCI 103:744–752. https://doi.org/10.1093/jnci/djr079

3. Esserman LJ (2017) The WISDOM Study: breaking the deadlock in the breast cancer screening debate. npj Breast Cancer 3:34. https://doi.org/10.1038/s41523-017-0035-5

4. Genome Canada (2018) Personalized risk assessment for prevention and early detection of breast cancer: Integration and Implementation. Genome Canada. In: genomecanada.ca. https://www.genomecanada.ca/en/personalized-risk-assessment-prevention-and-early-detection-breast-cancer-integration-and . Accessed 11 Nov 2018

5. Li J, Humphreys K, Eriksson L et al (2013) Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol 31:2249–2256. https://doi.org/10.1200/JCO.2012.44.5015

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA methylation at quantitative trait loci (mQTLs) varies with cell type and nonheritable factors and may improve breast cancer risk assessment;npj Precision Oncology;2023-09-27

2. Epidemiology of Breast Cancer in Sub-Saharan Africa;Breast Cancer Updates;2023-05-03

3. Of Screening, Stratification, and Scores;Journal of Personalized Medicine;2021-07-28

4. Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries;Breast Cancer;2021-07-24

5. Acceptability of risk‐stratified population screening across cancer types: Qualitative interviews with the Australian public;Health Expectations;2021-05-11